Recent data highlight that inflammatory Th17 cells fail to differentiate when CD95 expression is downregulated (81), suggesting that experiments with CD95L-expressing tumor cells may promote tumor graft rejection by inducing a Th17 differentiation-driven inflammatory environment. Here, FAS is linked to neoplasm.